REMS
Absorption: IV administration results in complete bioavailability; well absorbed following oral administration.
Distribution: Crosses the placenta.
Protein Binding: 99.9%.
Half-Life: 1420 hr.
Contraindicated in:
Use Cautiously in:
Seen primarily as manifestations of toxicity (hypercalcemia)
CV: arrhythmias, edema, hypertension, palpitations
Derm: pruritus, rash
EENT: conjunctivitis, photophobia, rhinorrhea
Endo: gout
F and E: hypercalcemia
GI: ↑liver function tests, anorexia, constipation, diarrhea, dry mouth, metallic taste, nausea, polydipsia, vomiting, weight loss
GU: ↓libido, ↑serum creatinine, albuminuria, azotemia
MS: bone pain, metastatic calcification, muscle pain
Drug-drug:
Stage 3 or 4 Chronic Kidney Disease
Stage 5 Chronic Kidney Disease
Lab Test Considerations:
Toxicity and Overdose:
NDC Code